Postmarketing Observational Study of Tisagenlecleucel for ALL or NHL Yields Promising Results
Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.
Non-Hodgkin Lymphoma
Why It’s Been So Hard to Conclusively Link Environmental Factors to Non-Hodgkin Lymphoma
Small studies, the absence of subtypes, and a historical lack of genetic information has stopped past studies from triggering meaningful public health change, a review asserts.
Pregnant Patients With Non-Hodgkin Lymphoma May Receive Chemotherapy
Pregnant patients with non-Hodgkin lymphoma may be able to receive CHOP-like chemotherapy during pregnancy with some risks.
Maternal, Fetal Considerations for the Treatment and Management of Lymphoma During Pregnancy
Although 1 in 1000 lymphoma diagnoses occurs in pregnancy, literature on best practices for treatment in this patient group is limited.
Obinutuzumab With Cytarabine Induction for Transplant-Eligible Mantle Cell Lymphoma
In a phase 2 trial, obinutuzumab added to induction therapy showed promising activity and tolerability for transplant-eligible mantle cell lymphoma.
Hepatosplenic T-cell Lymphoma: Recent Progress and Future Considerations
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.
Waldenström Macroglobulinemia Treated With Ixazomib Combination Therapy: Long-Term Follow-Up
Investigators measured ixazomib, dexamethasone, and rituximab combination treatment among patients with treatment-naive Waldenström macroglobulinemia.
2021 Update on Diagnosis, Risk Stratification, and Management of Cutaneous B-Cell Lymphomas
Researchers assessed diagnosis, risk-stratification, and management of 3 distinct subgroups of primary cutaneous lymphomas.
Managing Skin Flare Reactions in Patients Receiving Mogamulizumab for Cutaneous T-cell Lymphoma
Using a grading system for skin flare reactions increases potential for continuing administration of mogamulizumab despite the occurrence of this adverse effect.
Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans
Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes.
-
Loading...
-
Loading...
Next post in Lymphoma
